JP
Revvity Sites Globally
Select your location.
*e-commerce not available for this region.
Article
Selective targeting of mHTT presents novel therapeutic approach to huntington's disease
Huntington’s disease (HD) is a fatal neurodegenerative disorder that affects around 30,000 people in the US, with another 200,000 at risk of developing the condition. Despite extensive research into HD, there are currently no approved disease-modifying therapies available. Researchers from CHDI Foundation and Sangamo Therapeutics believe the ideal therapeutic will be one that eliminates the expression of mHTT without interfering with normal HTT function. In an effort to do just that, they have engineered zinc finger protein transcription factors (ZFP-TFs) to target the pathogenic CAG repeat and selectively lower mHTT as a therapeutic strategy. Read more about their research efforts.
For research use only. Not for use in diagnostic procedures.
To view the full content please answer a few questions
Download Resource
Selective targeting of mHTT presents novel therapeutic approach to huntington's disease